A Meta-Analysis of the Renal Safety of Isosmolar Iodixanol Compared With Low-Osmolar Contrast Media  by McCullough, Peter A. et al.
A
R
C
P
J
R
C
m
a
a
c
r
o
i
m
w
a
i
l
b
r
M
o
C
U
i
2
Journal of the American College of Cardiology Vol. 48, No. 4, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
PInvasive Cardiology
Meta-Analysis of the
enal Safety of Isosmolar Iodixanol
ompared With Low-Osmolar Contrast Media
eter A. McCullough, MD, MPH, FACC,* Michel E. Bertrand, MD, FACC,†
effrey A. Brinker, MD, FACC,‡ Fulvio Stacul, MD§
oyal Oak, Michigan; Baltimore, Maryland; Lille, France; and Trieste, Italy
OBJECTIVES We sought to compare the nephrotoxicity of isosmolar contrast medium (IOCM) iodixanol
with low-osmolar contrast media (LOCM) and to identify predictors of contrast-induced
nephropathy (CIN).
BACKGROUND Contrast-induced nephropathy is a serious complication of diagnostic and interventional
procedures.
METHODS Pooled individual patient data (n  2,727) from 16 double-blind, randomized, controlled
trials in which patients received either intra-arterial IOCM iodixanol (n  1,382) or LOCM
(n  1,345) were included. Patients were stratified according to chronic kidney disease
(CKD), diabetes mellitus (DM), or both. Outcome measures were the maximum increase in
serum creatinine (Cr) over baseline and the incidence of postprocedural CIN.
RESULTS The maximum Cr increase within 3 days after contrast medium (CM) administration was
significantly smaller in the iodixanol group compared with the LOCM group (0.06 mg/dl vs.
0.10 mg/dl, p  0.001), particularly in patients with CKD (0.07 mg/dl vs. 0.16 mg/dl, p 
0.004) and CKD  DM (0.10 mg/dl vs. 0.33 mg/dl, p  0.003). Contrast-induced
nephropathy, defined as an increase in Cr 0.50 mg/dl within 3 days after CM administra-
tion, occurred less frequently in the iodixanol group than in the LOCM group in all patients
(1.4% vs. 3.5%, p  0.001), in CKD patients (2.8% vs. 8.4%, p 0.001), and in CKD DM
patients (3.5% vs. 15.5%, p  0.003). Independent predictors of CIN included CKD, CKD 
DM, and use of LOCM.
CONCLUSIONS This meta-analysis of pooled data from 2,727 patients indicates that use of the IOCM
iodixanol is associated with smaller rises in Cr and lower rates of CIN than LOCM, especially
in patients with CKD or CKD  DM. (J Am Coll Cardiol 2006;48:692–9) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.02.073American College of Cardiology Foundation
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eontrast-induced nephropathy (CIN) remains one of the
ost clinically important complications of the use of iodin-
ted contrast medium (CM) (1). Contrast-induced nephrop-
thy is associated with considerably increased morbidity, in-
luding the need for short- and/or long-term hemodialysis or
enal transplantation (2). Most importantly, the development
f CIN is independently associated with increases in both
n-hospital and long-term mortality (2–5). Clinically, CIN
anifests as an abrupt decline in renal function occurring
ithin 3 days of administration of CM in the absence of an
lternative etiology (6). It is generally characterized by an
nitial increase in serum creatinine (Cr) concentration of at
east 0.5 mg/dl or by a relative increase of at least 25% from
aseline (6). Most episodes of CIN are self-limiting and
esolve within 10 days (6). However, there is evidence that
From the *Department of Medicine, Divisions of Cardiology and Preventive
edicine, William Beaumont Hospital, Royal Oak, Michigan; ‡Division of Cardi-
logy, The Johns Hopkins Medical Institutions, Baltimore, Maryland; †Division of
ardiology, University of Lille, Lille, France; and the §Institute of Radiology,
niversity of Trieste, Trieste, Italy. Drs. Brinker, Bertrand, and Stacul were
nvestigators and enrolled patients in individual trials included in the meta-analysis.i
Manuscript received October 3, 2005; revised manuscript received February 22,
006, accepted February 28, 2006.ven small persistent increases in Cr level are associated with
ncreased mortality (7,8).
Patient- and CM-related risk factors have been identified
hat contribute to the likelihood and extent of CIN (9).
lthough the risk of CIN is low in patients with well-
reserved renal function (10), chronic kidney disease (CKD)
ncreases the risk of CIN from the normal incidence of2%
p to 12% to 27% (9). Diabetes mellitus (DM) is possibly an
ndependent risk factor for CIN (9); however, patients with
oncomitant CKD and DM have an incidence of CIN as
igh as 50% (9,11). Characteristics of CM, such as osmo-
ality, might also influence the risk of CIN. Contrast media
an be categorized according to osmolality (e.g., high-
smolar CM [HOCM] approximately 2,000 mOsm/kg,
ow-osmolar CM [LOCM] 600 to 800 mOsm/kg, and
sosmolar CM [IOCM] 290 mOsm/kg) (6,12). In general,
he lower the osmolality of a CM is, the better its safety
rofile is (13). Although the chemical composition of CM
ionic vs. non-ionic, monomer vs. dimer) might also con-
ribute to the pathogenesis of CIN (12,13), significant
linical differences between various LOCM have not been
stablished (14–16). All LOCM are considered functionally
dentical in therapeutic guidelines issued by the European
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August 15, 2006:692–9 Contrast-Induced Nephropathyociety of Urogenital Radiology and the American College
f Radiology (9,17).
There is growing evidence that the IOCM iodixanol
educes the risk of CIN in patient populations with CKD or
KD with DM when compared with the LOCM iohexol
18,19), but small comparative trials of iodixanol with
OCM in general patient populations have been equivocal
20–22). These studies generally have shown that there are
o differences or only small, statistically insignificant differ-
nces in nephrotoxic effects between IOCM and LOCM,
ossibly because of insufficient statistical power (20–22).
he aim of this meta-analysis was to pool patient-level Cr
ata from randomized, controlled trials and compare Cr
hanges after administration of iodixanol versus all types of
OCM in a large patient population with differing levels of
isk for CIN, including a significant number of patients at
igh risk for renal complications.
ETHODS
his meta-analysis included prospective, double-blind, ran-
omized, controlled trials that compared iodixanol with
OCM in adult patients undergoing angiographic exami-
ations and reported Cr values at baseline and after CM
dministration. The clinical trial data source for this meta-
nalysis was the iodixanol database owned by GE Health-
are (formerly Amersham Health; Waukesha, Wisconsin),
epresenting data from all iodixanol angiographic clinical
rials sponsored by Amersham Health in Europe or the
nited States between 1991 and 2003. Individual patient-
evel data from all trials satisfying the retrospective criteria
or inclusion were pooled to create the database. Pooled data
ncluded demographic data (age, gender, weight), presence
f DM, CM administered (kind, concentration, and vol-
me), and Cr values at baseline and after administration.
Patient subgroups were formed after stratification by
KD and DM within the CM groups (IOCM vs. LOCM).
he presence of CKD was determined by assessing baseline
r concentration and estimated creatinine clearance (CrCl).
ll baseline Cr values were measured within 3 days before
M exposure. In 2,433 (89.2%) subjects, Cr was measured
24 h before CM administration. The CrCl was calculated
y applying the Cockroft-Gault formula to the baseline Cr
Abbreviations and Acronyms
CI  confidence interval
CIN  contrast-induced nephropathy
CKD  chronic kidney disease
CM  contrast media
Cr  creatinine
DM  diabetes mellitus
HOCM  high-osmolar contrast media
IOCM  isosmolar contrast media
LOCM  low-osmolar contrast mediaoncentration values: aCrCl ml⁄min 140 ageweight [kg]72 serum Cr mg⁄dl 0.85 for women
his equation closely correlates with measured CrCl (cor-
elation coefficient 0.83) and assesses renal function more
ccurately than Cr alone (23). Patients were identified as
aving CKD if their baseline Cr concentrations were1.50
g/dl for men or1.30 mg/dl for women or their CrCl was
60 ml/min.
Statistical analyses were performed on data pooled across
rials. The primary outcome was the maximum increase in
r within 3 days (baseline to highest value) after adminis-
ration of contrast. Results are expressed as mean  stan-
ard deviation, and the differences between the CM groups
ere analyzed with the Student t test. Secondary outcomes
ere the incidence of CIN, defined as an increase in Cr
oncentration of 0.50 mg/dl or 1.00 mg/dl over
aseline within 72 h after contrast administration. These
roportions were compared with the Fisher exact test.
or all tests, a p value  0.05 was considered statistically
ignificant. Quantitative analysis (meta-analysis) was con-
ucted on these data by calculating odds ratios (ORs) and
5% confidence intervals (CIs) for each study. A chi-square
est with n-1 degrees of freedom (df), where n is the number
f tested trials, was used to test for heterogeneity. This
eterogeneity analysis was used to guide the choice of effect
odel used for the analysis. Because there was no significant
eterogeneity (p  0.10) a fixed effects model was used. An
verall OR with 95% CI was calculated, with studies
eighted according to the Mantel-Haenszel method, with
eview Manager 4.2.7 software.
Multivariate logistic-regression analysis was used to de-
ermine predictors of CIN. The response variable was the
ncidence of CIN defined as an increase in Cr concentration
f 0.50 mg/dl. Odds ratios and their two-sided 95% CIs
re reported, and significance was determined by the posi-
ion of the 95% CIs. A CI not including 1 was considered
tatistically significant.
ole of the funding source. GE Healthcare sponsored the
riginal studies, collected the data in collaboration with
ndependent investigators, and provided site-monitoring
nd data management. Analyses were requested by the
uthors and performed by GE Healthcare statistical staff.
ESULTS
ixteen trials fulfilled the criteria for inclusion in the
eta-analysis (Table 1): 7 trials in coronary angiography or
ntervention (19,24–29), 5 trials in aortic or peripheral
ngiography (20,30–33), 1 trial in visceral and femoral
ngiography (34,35), 1 trial in cerebral angiography (36), 1
npublished trial in angiography, and 1 unpublished trial in
isceral/peripheral arteriography (Appendix).
From the total of 3,008 patients who were included in
hese trials, 281 (9.3%) were excluded from the meta-
nalysis for reasons including no or mixed CM administra-
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Contrast-Induced Nephropathy August 15, 2006:692–9ion and missing Cr measurements. Thus, the meta-analysis
as based on 2,727 evaluable patients: 1,382 (50.7%) in the
odixanol group and 1,345 (49.3%) in the LOCM group.
Pooled demographic and baseline characteristics of the
atient population are summarized in Table 2. Treatment
roups were comparable in terms of age and gender. The
emographics of subgroups stratified on the basis of renal
tatus, diabetes, or both conditions were also comparable.
atients given iodixanol and LOCM received comparable
olumes of CM (mean difference 6.2 ml), with a slight but
tatistically significant decrease in the total iodine dose
eceived by the iodixanol group compared with the LOCM
able 1. Characteristics of 16 Trials Included in Meta-Analysis (
Trial Diagnostic Procedure, Reference
No. of Patients
Included in
the Trial
E
i
ardioangiography, Kløw et al. (27) 80
ardioangiography, Tveit et al. (29) 94
ardioangiography, Andersen et al. (24) 76
ardioangiography, Manninen et al. (28) 130
ardioangiography, data on file 50
ardioangiography, Aspelin et al. (19) 135
ardioangiography, Hill et al. (26) 200
emoral angiography, Pugh et al. (20) 100
emoral angiography, Thorstensen et al. (31) 74
ortoangiography, Singh et al. (30) 60
ortoangiography, Jakobsen et al. (33) 16
emoral angiography, Verow et al. (32) 145
ngiography (visceral and femoral), data on file 110
ngiography (visceral and femoral),
Siegel et al. (35)  Rosenblum et al. (34)
100
erebral angiography, Poirier et al. (36) 100
TCA, Bertrand et al. (25) 1,541
otal 3,008
Indicates LOCM ionic dimer ioxaglate.
IOCM  isosmolar contrast media (iodixanol); LOCM  low-osmolar contrast
TCA  percutaneous transluminal coronary angioplasty.
Table 2. Demographic Information
Variable
All Patien
(n  2,727
Age, yrs (mean  SD) 61.5  11
Male gender 1,999
CKD 735
DM 568
Mean baseline Cr (mg/dl)
With CKD 1.47  1.0
Without CKD 1.00  0.1
CKD and DM 232
Total volume (ml) (mean  SD) 179.0  94
Total dose (g iodine) (mean  SD) 57.2  30
Indication for CM
Cardioangiography 2,072
Arteriography 655CKD  chronic kidney disease; CM  contrast medium; DM  dia
low-osmolar contrast media.roup, mainly owing to the lower iodine concentration of
odixanol.
Patients received different formulations of CM. The
,382 iodixanol patients were given either the 270 mg I/ml
r the 320 mg I/ml formulation. Patients receiving non-
onic, monomeric LOCM were given iohexol 300 mg I/ml
r 350 mg I/ml (n 381), iopamidol 300 mg I/ml (n 69),
r iopromide 300 mg I/ml or 370 mg I/ml (n  106). The
emainder of patients given LOCM were given the ionic
imer, ioxaglate 320 mg I/ml (n  789).
Serum Cr measurements were available at baseline for all
atients, but the timing of subsequent Cr measurements was
,24–36)
. of Patients
e for Inclusion
Meta-Analysis
No. of Patients
Creatinine
Measurements
IOCM
Iodixanol LOCM Baseline
Day
1 2 3
72 35 37 X X X
92 49 43* X X X
74 36 38* X X X
128 68 60 X X
49 25 24 X X X
132 66 66 X X X
195 97 98 X X X X
93 47 46 X X X
65 34 31 X X
60 40 20 X X
16 8 8 X X X X
144 75 69 X X
101 49 52 X X X
97 49 48* X X X X
95 50 45 X X X X
1,314 654 660* X X X
2,727 1,382 1,345
(non-ionic monomers [iohexol, iopromide, iopamidol] and ionic dimer ioxaglate);
Contrast Media
p Value
IOCM Iodixanol
(n  1,382)
LOCM
(n  1,345)
61.2  11.9 61.8  11.6 NS
1,011 988 NS
362 373 NS
293 275 NS
1.43  0.89 1.50  1.10 NS
1.01  0.18 1.00  0.18 NS
115 117 NS
175.9  91.3 182.1  97.8 0.09
55.4  29.1 58.9  31.0 0.003
1,038 1,034 NS
344 311 NS19,20
No
ligibl
n thets
)
.8
0
8
.6
.1betes mellitus; IOCM  isosmolar contrast media; LOCM 
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August 15, 2006:692–9 Contrast-Induced Nephropathyariable with 99% of subjects with measurements within
he first 48 h (Fig. 1). Only 18.3% of patients had their final
r values measured on day 3 or later.
The overall population examined in this study was het-
rogeneous with respect to risk factors for and the incidence
f CIN. However, greater homogeneity was found within
atient subgroups defined on the basis of common risk
actors (DM and CKD), which enabled comparison of
ncreases in Cr and CIN incidence within these subgroups.
nly two of the trials were designed to examine the renal
afety of CM in patients with CKD (19,33).
The maximum measured increases in Cr from baseline
fter contrast administration in all patients and in patient
ubgroups up to day 3 are given in Figure 2. A comparison
f all patients, regardless of risk factors, showed that the
aximum increase in Cr was significantly less in patients
reated with iodixanol than with LOCM (0.06 mg/dl vs.
.10 mg/dl, p 0.001). A similar result was obtained in the
ubgroups of patients with CKD (0.07 mg/dl vs. 0.16
g/dl, p  0.004) and without CKD (0.06 mg/dl vs. 0.08
g/dl, p  0.01). A significantly lesser change from
aseline was also observed for patients with DM alone
igure 1. The proportion of patients with a creatinine measurement
vailable on the days after administration of contrast media (CM). Patients
eceived either isosmolar contrast media (IOCM) (iodixanol) or low-
smolar contrast media (LOCM). Pre-CM  baseline before contrast
edia was given.
igure 2. Maximal absolute increase in the creatinine (Cr) concentration
rom baseline to day 3, after contrast administration. The differences in Cr
etween the IOCM iodixanol and LOCM groups were compared with thet
tudent t test. Patients received either IOCM or LOCM. CKD chronic
idney disease; DM diabetes mellitus; other abbreviations as in Figure 1.reated with iodixanol compared with LOCM (0.06 mg/dl
s. 0.11 mg/dl, p  0.003). Finally, in high-risk patients
ith CKD  DM, the maximal Cr increase was signifi-
antly smaller in the iodixanol group compared with the
OCM group (0.10 mg/dl vs. 0.33 mg/dl, p  0.003).
able 3 shows that the maximum serum Cr rise was lower
ith iodixanol versus non-ionic or ionic LOCM.
The incidence of CIN (Cr 0.50 mg/dl) occurring within
2 h after contrast administration among the iodixanol- and
OCM-treated groups is summarized in Table 4. The inci-
ence of CIN was also lower in patients given iodixanol than
n those given non-ionic monomeric LOCM (2.4% vs. 6.2%,
R 0.37, 95% CI 0.20 to 0.69, p 0.002). This difference
as amplified in patients with CKD (5.1% vs. 13.3%, OR
.35, 95% CI 0.16 to 0.79, p  0.01). A similar trend was
bserved in patients given iodixanol rather than ionic dimeric
OCM (0.6% vs. 1.6%, OR  0.38, 95% CI 0.14 to 1.07,
 0.09), with a greater difference in patients with CKD
0.5% vs. 4.4%, OR 0.12, 95% CI 0.01 to 0.94, p 0.02).
The incidence of CIN in the pooled population, with the
ore stringent definition for increase in Cr of1.00 mg/dl,
as 0.1% in the iodixanol group and 1.2% in the LOCM
roup (OR  0.06, 95% CI 0.01 to 0.45, p  0.001). The
ncidence of CIN was also significantly lower among pa-
ients treated with iodixanol than with LOCM in patient
ubgroups with CKD (0.3% vs. 3.8%, OR  0.07, 95% CI
.01 to 0.54, p  0.001) and CKD  DM (0% vs. 7.8%, p
0.003).
A chi-square test (df  9) for heterogeneity applied for
rials in which at least one subject experienced CIN (10 of
6) was not significant (p  0.25), indicating homogenous
ncidence rates for CIN among these trials (Fig. 3). Accord-
ng to this result, the fixed effects model was used to test the
verall effect. The test for the overall effect showed a
ignificant difference in favor of iodixanol (overall OR 
.39, 95% CI 0.23 to 0.66, p  0.0004). Given the strong
nfluence of the trial by Aspelin et al. (19)—which had the
owest OR, a modest sample size, and highest weight—the
eta-analysis was re-run without including this trial. Again,
he test for heterogeneity was not significant (p  0.52) and
able 3. Maximum Increase in Serum Cr After Contrast
xposure: Analysis by Chemical Composition and
rial Comparison
CM Composition n
Maximum
Cr Increase
(mg/dl) p Value
on-ionic, dimeric IOCM (iodixanol) 594 0.12  0.16
on-ionic, monomeric LOCM
(iohexol, iopromide, iopamidol)
552 0.18  0.43 0.001
on-ionic, dimeric IOCM (iodixanol) 788 0.02  0.16
onic, dimeric LOCM (ioxaglate) 788 0.05  0.21 0.01
rom baseline to day 3.
CM  contrast media; Cr  creatinine; IOCM  isosmolar contrast media;
OCM  low-osmolar contrast media.he fixed effects test for the overall effect showed a signifi-
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Contrast-Induced Nephropathy August 15, 2006:692–9ant difference in favor of iodixanol (overall OR  0.55,
5% CI 0.30 to 0.99).
Independent predictors of CIN (Cr 0.50 mg/dl)
dentified through logistic regression analysis were: CKD
OR  3.1, 95% CI 1.7 to 5.6), combination of CKD 
M (OR 2.7, 95% CI 1.4 to 5.1), and the use of LOCM
OR  2.6, 95% CI 1.5 to 4.5). Age, DM alone, and CM
olume were found not to be independent predictors of CIN
n the model.
ISCUSSION
his meta-analysis was performed with pooled individual
ata of patients given iodixanol (n  1,382) or a LOCM
n  1,345) intra-arterially for a variety of diagnostic and
nterventional procedures. In all patients, the increase in Cr
ssociated with administration of CM was smaller in pa-
ients given iodixanol than in the pooled LOCM popula-
ion. The lesser increase in Cr observed with iodixanol was
ssociated with a reduced incidence of CIN according to
oth standard (0.50 mg/dl) and stringent (1.00 mg/dl)
efinitions. The largest absolute difference in the incidence
able 4. Rates of Contrast-Induced Nephropathy Defined as a R
Population
Number of Patients
IOCM Iodixanol/LOCM
IOCM Iod
n (%)
ll 1,382/1,340* 19 (1.4
CKD 362/371 10 (2.8
CKD 1,020/969 9 (0.9
CKD  DM 115/116 4 (3.5
CKD  DM 247/255 6 (2.4
CKD  DM 178/158 1 (0.6
CKD  DM 842/811 8 (1.0
Five patients without follow-up Cr value within 3 days.
CI  confidence interval; CKD  chronic kidney disease; Cr  serum creatinin
ontrast media; OR  odds ratio.
Outcome: Contrast Induced Nephropathy (CIN), defined as
Trial (indication, reference) IOCM LOCM
n/N n/N
Femoral angiography, Pugh 93          2/47           0/46      
Femoral angiography, Verow 95       1/75           0/69      
Cerebral angiography, Poirier 96 3/50           1/44      
Angiography, Data on file 96 2/49           4/49      
PTCA, Bertrand 2000 5/654         12/660  
Cardioangiography, Hill 94          2/97           6/98      
Angiography, Siegel 96, Rosenblum 96  0/49           1/47      
Aortoangiography, Jakobsen 96   2/8             5/8        
Aortoangiography, Singh 93         0/40           1/20      
Cardioangiography, Aspelin 2003       2/66           17/66    
    5311)IC %59( latoT            1107
Total events: 19 (IOCM), 47 (LOCM)
Test for heterogeneity: Chi² = 11.32, df = 9 (p = 0.25), I² = 20.5
Test for overall effect: Z = 3.52 (p = 0.0004)
0.01
Favor
igure 3. Summary of all trials in which at least 1 subject experienced contr
he chi-square test for heterogeneity was not significant (p  0.25), indica
esult, the fixed effects model was chosen to test the overall effect. The test f
OCM, with the odds ratio (OR)  0.39, 95% confidence interval (CI) 0.
hich at least 1 patient experienced CIN (10 of 16), and test for the overhe Review Manager 4.2.7. n  number of patients who experienced CIN d
easurements; PTCA  percutaneous transluminal coronary angioplasty (trialf CIN found between patients given iodixanol and those
iven LOCM was in subgroups with CKD or CKDDM.
atient-related predictors of CIN were found to be CKD
nd CKD  DM but not DM alone. Use of LOCM was a
rocedure-related predictor of increased CIN risk. The
olumes of contrast in the two groups were similar (approx-
mately 180 ml) and in the range where CIN has been found
o be a serious complication in patients undergoing cardio-
ascular procedures (3,37). These data are internally consis-
ent with the hypothesis that iodixanol (290 mOsm/kg) is
ess nephrotoxic than LOCM agents with osmolalities
anging from 600 to 800 mOsm/kg in the volumes of
ontrast used in these trials.
revious studies of nephrotoxicity. Previous clinical trials
ave demonstrated that as osmolality is reduced, lesser rates
f CIN are observed (38,39). In a prospective, randomized
rial involving 1,196 patients, 213 patients had CKDDM
38). The incidence of CIN (Cr 0.50 mg/dl) in this
igh-risk population was 33.3% in the LOCM group and
7.7% in the HOCM group. No differences were found
etween the two types of CM in patients with normal renal
Cr 0.5 mg/dl: Analysis by Patient Subgroup
l LOCM
n (%) OR (95% CI)
Fisher Exact Test
p Value
47 (3.5) 0.38 (0.22–0.66) 0.001
31 (8.4) 0.31 (0.15–0.65) 0.001
16 (1.7) 0.53 (0.23–1.21) 0.16
18 (15.5) 0.20 (0.06–0.60) 0.003
13 (5.1) 0.46 (0.17–1.24) 0.16
3 (1.9) 0.29 (0.03–2.84) 0.35
13 (1.6) 0.59 (0.24–1.43) 0.28
 diabetes mellitus; IOCM  isosmolar contrast media; LOCM  low-osmolar
rease ≥0.5 mg/dl                
OR (fixed) Weight OR (fixed)
95% CI % 95% CI
1.01 5.11 [0.24, 109.39]      
1.08 2.80 [0.11, 69.85]       
2.12 2.74 [0.28, 27.39]       
8.12 0.48 [0.08, 2.74]        
25.10 0.42 [0.15, 1.19]        
12.38 0.32 [0.06, 1.64]        
3.21 0.31 [0.01, 7.88]        
7.94 0.20 [0.02, 1.71]        
4.15 0.16 [0.01, 4.12]        
34.90 0.09 [0.02, 0.41]        
100.00 0.39 [0.23, 0.66]
1 10 100
Favors LOCM
duced nephropathy (CIN) defined as a rise in Cr 0.50 mg/dl (10 of 16).
omogenous incidence rates for CIN among these trials. According to this
overall effect showed a significant difference in favor of the group receiving
0.66, p  0.0004 (19,20,25,26,30,32–36). Heterogeneity test for trials in
ect with trials weighted according to the Mantel-Haenszel method, withise in
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August 15, 2006:692–9 Contrast-Induced Nephropathyunction, regardless of the presence of DM. Similarly, the
resent meta-analysis showed that reducing osmolality the
ext level from LOCM to IOCM reduced the incidence of
IN in patients with CKD but did not reduce the incidence
f CIN in patients without CKD.
A smaller meta-analysis (n  697) previously com-
ared the nephrotoxicity of the IOCM iotrolan (280 mg
/dl) with LOCM, including iopamidol (300 mg I/dl),
opromide (300 mg I/dl), and iohexol (300 mg I/dl) in a
eneral population (39). Consistent with the present
eta-analysis of iodixanol, the increase in Cr at 48 h was
ignificantly smaller after iotrolan than LOCM in all
atients as well as in patients with CKD. This study
ffers further support for the notion that IOCM agents
ave the lowest degree of nephrotoxicity.
Our findings are consistent with those from a small
ead-to-head comparison of iodixanol and iohexol in pa-
ients with CKD that is not part of the iodixanol database
wned by GE Healthcare (18). In that study, 102 patients
ith pre-existing CKD (Cr 1.5mg/dl) were randomized
o iodixanol 320 mg I/dl or 270 mg I/dl (n  54) or iohexol
00 mg I/dl (n 48) (18). With CIN defined as an increase
f 25% in Cr concentration from baseline, the incidence
f CIN was 3.7% and 10.0% in the iodixanol and iohexol
roups, respectively. Because of the small sample size, the
ifference was not statistically significant. Nevertheless,
hese data compare favorably with the statistically signifi-
ant results of the current study, in which the incidence of
IN (Cr 0.50 mg/dl) in patients with CKD was 2.8%
ith iodixanol and 8.4% with LOCM (p  0.001).
A recently presented percutaneous coronary intervention
PCI) registry involving 7,769 patients compared 3 years’
ata with LOCM (iohexol; n 5,855), followed in the next
ear with IOCM (iodixanol; n  1,914) (40). Baseline
emographics were similar in those who received iohexol
nd iodixanol, however, Cr was higher in the iohexal period,
1.18  0.01 [mean  SD] vs. 1.12  0.02, p  0.05).
here were significantly more patients with DM (26% vs.
9%, p  0.01) and hypertension (58% vs. 65%, p  0.01)
n the group receiving iodixanol. The prevalence of CIN,
efined as a rise in Cr 25% within 24 h after PCI, was
.57% with iohexol and 5.26% with iodixanol (30.5%
elative reduction, p  0.01). The authors concluded that
odixanol use in a general population of patients is associ-
ted with reduced risk for CIN, consistent with this
eta-analysis.
redictors of contrast-induced nephropathy. Patient-
elated risk factors for CIN have previously been established
o include chronic CKD and DM (41). The incidence of
OCM-related CIN in diabetic patients with CKD has
anged from 5.7% to 29.4% in prior studies (41,42). Our
eported rate of CIN (15.5%) is well within this range.
urthermore, this meta-analysis confirms the primary im-
ortance of CKD and CKD  DM as risk factors for CIN.
se of LOCM was found to be an independent procedural
redictor of CIN, but volume of CM was not. The latter results seem consistent with a retrospective analysis demon-
trating no significant correlation between iodixanol volume
nd Cr increase in patients with CKD (43).
ontrast osmolality and renal injury. Contrast media is
lassified according to osmolality, which reflects the total
article concentration of the solution (the number of mol-
cules dissolved in a specific volume). Over the past 40
ears, the osmolalities of available CM have been gradually
ecreased to physiological levels. In the 1950s, only HOCM
e.g., diatrizoate) with osmolality 5 to 8 times that of plasma
ere available (44). In the 1980s, LOCM agents such as
ohexol, iopamidol, and ioxaglate were introduced. Al-
hough these are classified as LOCM, their osmolality is 2
o 3 times greater than that of plasma (44). In the 1990s,
OCM with the same physiologic osmolality as blood were
eveloped (e.g., iodixanol) (44). Red blood cell deformation,
ystemic vasodilation, intrarenal vasoconstriction, as well as
irect renal tubular toxicity are all more common in contrast
gents with osmolality greater than that of blood (44).
tudy strengths and limitations. A major strength of this
tudy is the size and quality of the database used. All of the
tudies were randomized, prospective trials in which the
reatment allocation was iodixanol versus LOCM. Analysis
f the pooled, patient-level (as opposed to tabular) data
ermitted estimation of the difference in the incidence of
ephrotoxicity between iodixanol and LOCM in all patients
nd in specific patient subgroups. It is important to note
hat despite variations in baseline risk, CM dose, timing of
r measurements, and comparator LOCM, significant
ifferences in CIN were consistently observed between
odixanol and LOCM agents. Meta-analyses that include
tudies where there is no randomization of CM and no
atient-level data are unable to quantify baseline risk or
erform subgroup analyses and, very importantly, might fail
o find existing differences between specific CM.
An additional strength of our study was the inclusion of
ll trials (including 2 unpublished) in the database to avoid
ublication bias, which is a common threat to the validity of
eta-analyses. Given that the 2 unpublished studies were
mall, underpowered, and neutral on CIN (iodixanol vs.
OCM), their exclusion from this analysis would bias
esults toward the hypothesis that iodixanol has greater
enal safety than LOCM.
Operator bias is a potential threat to validity of any
eta-analysis focusing on the reduction of a procedural
omplication. That is, the actions of operators performing
ontrast procedures with the aim of reducing CIN might
nfluence the outcomes. This was handled by the use of
atient-level data, multivariate analysis controlling for
he volume of contrast used, and by restrictive protocols
hat did not allow the use of N-acetylcysteine or any
ther investigational prophylactic therapy (45). However,
he operators might have influenced the outcomes in our
rials in that the amount or type of intravenous hydration
iven before and after the contrast exposure was not
ecorded in our database.
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Contrast-Induced Nephropathy August 15, 2006:692–9Another limitation of this meta-analysis is that the early
iming of the Cr measurements might have resulted in an
nderestimation of the incidence of CIN in both experi-
ental groups. Although the maximum increase in Cr
ndicative of CIN is generally observed up to 3 days after
dministration of CM (6) or even 3 to 5 days after CM
dministration (46), the majority of Cr measurements were
vailable only for day 1 or day 2, and some cases of CIN
ight have been missed. However, it is unlikely that serious
ases of CIN were missed, because they are usually detected
ithin the first 24 h after the contrast exposure (47).
Finally, outcome data on the longer-term consequences
f exposure to iodixanol versus LOCM were not available.
owever, prior studies have demonstrated that even tran-
ient rises in Cr translate into differences in adjusted
ong-term outcomes after PCI (7,48). Mild sustained in-
reases in Cr have been observed to increase the risk of
eath by 3-fold over 8 years (8). Thus, the impact of this
tudy on clinical practice, with the anticipated sharp in-
rease in iodinated contrast media with computed tomo-
raphic coronary angiography, is 2-fold: 1) the presence of
KD and DM should be known a priori, and 2) iodixanol
hould be considered in those with CKD and in particular
hose with CKD and DM.
onclusions. The results of this meta-analysis indicate
hat intra-arterial administration of the IOCM iodixanol
s associated with a reduced risk for CIN compared with
OCM. The reduction in the mean Cr increase and in
he incidence of CIN is greatest in patients with CKD or
KD  DM. These results support the use of iodixanol to
revent contrast-related renal dysfunction in patients at risk
or CIN.
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PPENDIX
or a description of the previously unpublished trials included
n the meta-analysis, please see the online version of this article.
